Drug Profile
Pegloticase - Horizon Therapeutics
Alternative Names: KRYSTEXXA; Methoxypolyethylene glycol uricase; PEG urate oxidase; PEG-uricase; PEGylated uricase; Polyethylene glycol-uricase; Puricase; Urate-oxidase-PEGLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Duke University; Mountain View Pharmaceuticals
- Developer Horizon Pharma Rheumatology; Savient Pharmaceuticals
- Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gout
Most Recent Events
- 10 Nov 2023 Updated efficacy data from the phase IV MIRROR RCT trial in Gout presented at ACR Convergence 2023 (ACR-2023)
- 31 May 2023 Updated efficacy data from the phase IV MIRROR RCT trial in Gout released by Horizon Therapeutics
- 14 Nov 2022 Efficacy data from the phase IV MIRROR OL trial in Gout presented at the American College of Rheumatology Convergence 2022 (ACR-2022)